US healthcare spend slows on generic growth, says journal

Share this article:
The rate of growth in US healthcare spending slowed to its lowest rate since 1998 in 2007 on lethargic retail prescription drug spending and government administration, according to a Health Affairs analysis.

The journal found that US healthcare spending increased 6.1% in 2007 to $2.2 trillion, or $7,421 per person. Spending on prescription drugs grew by a mere 4.9%, while other healthcare services grew at about the same rate as or faster than in 2006.

The slowdown in spending on prescription drugs is attributable largely to increasing generic encroachment on branded drugs, driven in part by rising public spending on drugs. Spending growth from private sources accelerated in 2007 as public spending slowed, the journal found, “but public spending growth has continued to outpace private sources since 2002.”

In November, IMS Health revised its 2009 forecast for US drug spending growth down to 1%-2%, with sales between $287 billion and $297 billion.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.